Back to Results

Altamira Therapeutics Ltd (CYTOF)

Altamira Therapeutics Ltd. is a common stock listing of a healthcare company focused on preclinical-stage biopharmaceutical research and development. The company works in Switzerland, Australia, the United States, and Europe, and is based in Hamilton, Bermuda. Its programs include peptide-based nanoparticle technology for RNA delivery to extrahepatic tissues through the xPhore platform, as well as Bentrio, a drug-free nasal spray designed for protection against airborne viruses and allergens. Altamira is also advancing AM-401 for KRAS-driven cancer, AM-411 for rheumatoid arthritis, and AM-125, which has reached the post-phase II stage for intranasal treatment of vertigo. The company was previously known as Auris Medical Holding Ltd. and adopted its current name in July 2021.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-CYTO.F
$0.072
-19.1% Downside
Overvalued
Not available
Not available
Weak
0.0%
0.1x
505.819 K
1.073 M
60.8%
72.0%
-21.0
77.8%
Valuation • Fair Value

Altamira Therapeutics Ltd (OTC-CYTO.F) Fair Value by Valuation Model

Review the available estimates for Altamira Therapeutics Ltd (OTC-CYTO.F), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.072

Estimated downside of 19.1% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.072

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Altamira Therapeutics Ltd (OTC-CYTO.F) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Altamira Therapeutics Ltd (OTC-CYTO.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Altamira Therapeutics Ltd (OTC-CYTO.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Altamira Therapeutics Ltd (OTC-CYTO.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

0

Weak quality score that deserves closer review.

Altman Z-Score

-21.0

Lower score that deserves closer risk review.

FCF / Net Income

77.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Altamira Therapeutics Ltd (OTC-CYTO.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Altamira Therapeutics Ltd (OTC-CYTO.F)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Altamira Therapeutics Ltd (OTC-CYTO.F). No upcoming dividend amount or event date is currently available.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Altamira Therapeutics Ltd (OTC-CYTO.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Altamira Therapeutics Ltd (OTC-CYTO.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Altamira Therapeutics Ltd (OTC-CYTO.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Buy

The weekly technical read for Altamira Therapeutics Ltd (OTC-CYTO.F) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Altamira Therapeutics Ltd (OTC-CYTO.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Altamira Therapeutics Ltd (OTC-CYTO.F) Stock FAQ

Data-supported answers about Altamira Therapeutics Ltd (OTC-CYTO.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.072
Estimated downside 19.1%
Valuation Rating
Overvalued
Estimated downside of 19.1%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Altamira Therapeutics Ltd (OTC-CYTO.F) is $0.072. This implies an estimated downside of 19.1% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 19.1% versus the current market price.

The current financial health read for Altamira Therapeutics Ltd (OTC-CYTO.F) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Altamira Therapeutics Ltd (OTC-CYTO.F).

The current market capitalization listed for Altamira Therapeutics Ltd is 505.819 K.

The current enterprise value listed for Altamira Therapeutics Ltd is 1.073 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Altamira Therapeutics Ltd is OTC-CYTO.F, and the stock is listed on OTC Markets.

Altamira Therapeutics Ltd (OTC-CYTO.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Altamira Therapeutics Ltd is 60.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Altamira Therapeutics Ltd is 72.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,027.7 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 650.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 266.2 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 191.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 157.7 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 128.8 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 101.9 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 100.8 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.801 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.423 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.198 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.653 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 29.504 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.446 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.628 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 11.943 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.202 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.884 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.161 B